STAT6 and cancer: Figure 6 shows our working model for the regulation of PG production in FDC based on the current experimental results. Indeed, STAT6 inhibitors or IL-4 antagonists are currently considered therapeutic options for immunopathologic diseases [30,31,32,33]. Considering the important roles that Akt plays in many physiological conditions, the effects of Akt inhibitors should be carefully analyzed when they are used as therapeutics in cancer, infectious diseases, and inflammation [34,35,36].